Literature DB >> 34373091

Molecular Pathology of Prostate Cancer.

Ibrahim Kulac1, Martine P Roudier2, Michael C Haffner3.   

Abstract

Molecular profiling studies have shed new light on the complex biology of prostate cancer. Genomic studies have highlighted that structural rearrangements are among the most common recurrent alterations. In addition, both germline and somatic mutations in DNA repair genes are enriched in patients with advanced disease. Primary prostate cancer has long been known to be multifocal, but recent studies demonstrate that a large fraction of prostate cancer shows evidence of multiclonality, suggesting that genetically distinct, independently arising tumor clones coexist. Metastatic prostate cancer shows a high level of morphologic and molecular diversity, which is associated with resistance to systemic therapies. The resulting high level of intratumoral heterogeneity has important implications for diagnosis and poses major challenges for the implementation of molecular studies. Here we provide a concise review of the molecular pathology of prostate cancer, highlight clinically relevant alterations, and discuss opportunities for molecular testing.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AR; ERG; Intratumoral heterogeneity; Metastasis; Morphology; PTEN; Prostate cancer

Year:  2021        PMID: 34373091     DOI: 10.1016/j.path.2021.05.004

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  3 in total

1.  Personalized 3-Gene Panel for Prostate Cancer Target Therapy.

Authors:  Sanda Iacobas; Dumitru Andrei Iacobas
Journal:  Curr Issues Mol Biol       Date:  2022-01-15       Impact factor: 2.976

Review 2.  The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.

Authors:  Pengfei Xu; Logan J Wasielewski; Joy C Yang; Demin Cai; Christopher P Evans; William J Murphy; Chengfei Liu
Journal:  Biomedicines       Date:  2022-07-22

3.  In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis.

Authors:  Susanne G Kidd; Mari Bogaard; Kristina T Carm; Anne Cathrine Bakken; Aase M V Maltau; Marthe Løvf; Ragnhild A Lothe; Karol Axcrona; Ulrika Axcrona; Rolf I Skotheim
Journal:  Mol Oncol       Date:  2022-06-18       Impact factor: 7.449

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.